STOCK MARKET Wockhardt shares surge 3% after positive CDSCO panel nod for new antibiotic Zaynich Mar 30, 2026
BUSINESS Wockhardt’s Zaynich receives favourable recommendation for Gram-negative infections treatment Mar 30, 2026
CORPORATES Wockhardt files Marketing Authorisation Application to EMA for antibiotic WCK 5222 Jan 7, 2026
Wockhardt shares rally sharply over 18% as US FDA accepts NDA for breakthrough antibiotic Zaynich Dec 1, 2025
Wockhardt Q1 Results: Shares drop 3% as EBITDA falls 20.9% YoY Rs 72 crore, revenue flat at Rs 739 Aug 8, 2025
Wockhardt shares surge 10% as flagship antibiotic Zaynich demonstrates breakthrough clinical success Jan 31, 2025
Wockhardt’s Zaynich achieves 96.8% clinical cure rate, sets new benchmark in Phase III global study Jan 31, 2025
Wockhardt shares surge nearly 5% after CDSCO approval for revolutionary antibiotic Miqnaf Jan 3, 2025